Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis

Rajesh B. Singh; Saravana K. Jagannathan; Kumar Vineet

doi:10.1055/s-0045-1808094

South Asian Journal of Cancer, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0045-1808094

Original Article

Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis

Rajesh B. Singh

¹Surgical Oncology (Orthopedics Oncology), Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India

,

Saravana K. Jagannathan

¹Surgical Oncology (Orthopedics Oncology), Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India

,

Kumar Vineet

²Department of Surgical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India

› Institutsangaben

Abstract

Objectives

Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a high recurrence rate. Using denosumab or its biosimilar in a neoadjuvant setting can facilitate limb-preserving surgery and reduce recurrence rates, with minimal side effects.

Material and Methods

In this clinical audit, we retrospectively analyzed the impact of denosumab biosimilar (DB) on Campanacci grade 3 GCTB, the most aggressive form of these tumors.

Statistical Analysis

Means and standard deviations were used for normally distributed continuous variables, medians and ranges for nonnormal continuous variables, and percentages for categorical variables.

Results

All cases received two doses of DB on days 0 and 14, resulting in a mean lesion size reduction of 17.75%.

Conclusion

Our findings suggest that this treatment regimen can significantly improve outcomes for patients with aggressive GCTB, aiding orthopaedic oncologists in managing these challenging cases more effectively.

Keywords

GCT - denosumab - biosimilar - tumor - recurrence

Volltext

Referenzen

References
1 Becker RG, Galia CR, Pestilho JFCS, Antunes BP, Baptista AM, Guedes A. Giant cell tumor of bone: a multicenter epidemiological study in Brazil. Acta Ortop Bras 2024; 32 (01) e273066
2 Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant cell tumor of bone - an overview. Arch Bone Jt Surg 2016; 4 (01) 2-9
3 Borkowska AM, Szumera-Ciećkiewicz A, Szostakowski B, Pieńkowski A, Rutkowski PL. Denosumab in giant cell tumor of bone: multidisciplinary medical management based on pathophysiological mechanisms and real-world evidence. Cancers (Basel) 2022; 14 (09) 2290
4 Cooper AS, Travers B. Surgical Essays. London, England: Cox Longman & Co; 1818: 178-179
5 Jaffe HL, Lichtenstein L, Portis RB. Giant cell tumor of bone. Its pathologic appearance, grading, supposed variants and treatment. Arch Pathol (Chic) 1940; 30 (03) 993-1031
6 Wu PF, Tang JY, Li KH. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects. Tumour Biol 2015; 36 (02) 495-501
7 Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ, Soucacos PN. Giant cell tumor of bone revisited. SICOT J 2017; 3: 54
8 Tsukamoto S, Mavrogenis AF, Kido A, Errani C. Current concepts in the treatment of giant cell tumors of bone. Cancers (Basel) 2021; 13 (15) 3647
9 Branstetter DG, Nelson SD, Manivel JC. et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012; 18 (16) 4415-4424
10 Puri A, Agarwal M. Treatment of giant cell tumor of bone: current concepts. Indian J Orthop 2007; 41 (02) 101-108
11 Konishi E, Outani H, Mano M. et al. Giant cell tumor of bone - analysis of 213 cases involving extra-craniofacial bones. Pathol Int 2021; 71 (08) 500-511
12 Purohit S, Pardiwala DN. Imaging of giant cell tumor of bone. Indian J Orthop 2007; 41 (02) 91-96
13 Rekhi B, Dave V. Giant cell tumor of bone: an update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses. Histol Histopathol 2023; 38 (02) 139-153
14 Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004). Rare Tumors 2009; 1 (02) e52
15 van Langevelde K, McCarthy CL. Radiological findings of denosumab treatment for giant cell tumours of bone. Skeletal Radiol 2020; 49 (09) 1345-1358
16 Srikanth E, Kancherla NR, Arvind B. et al. Campanacci grade III giant cell tumors of distal end radius treated with wide excision and reconstruction: a retrospective case series. Cureus 2022; 14 (08) e27818
17 Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone-a review and future management considerations. Curr Oncol 2013; 20 (05) e442-e447
18 Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011; 469 (02) 591-599
19 Hu P, Zhao L, Zhang H. et al. Recurrence rates and risk factors for primary giant cell tumors around the knee: a multicentre retrospective study in China. Sci Rep 2016; 6: 36332
20 Li H, Gao J, Gao Y, Lin N, Zheng M, Ye Z. Denosumab in giant cell tumor of bone: current status and pitfalls. Front Oncol 2020; 10: 580605